Morgan Stanley
HZNP

Morgan Stanley’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Morgan Stanley’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,839,854
Closed -$329M – 8079
2023
Q3 		$329M Sell
2,839,854
-162,095
-5% -$17.4M 0.03% 507
2023
Q2 		$309M Buy
3,001,949
+881,935
+42% +$93M 0.03% 551
2023
Q1 		$231M Buy
2,120,014
+618,630
+41% +$68.4M 0.02% 639
2022
Q4 		$171M Sell
1,501,384
-201,996
-12% -$16.8M 0.02% 758
2022
Q3 		$105M Buy
1,703,380
+332,364
+24% +$23.2M 0.01% 859
2022
Q2 		$109M Buy
1,371,016
+110,363
+9% +$10.5M 0.01% 871
2022
Q1 		$133M Sell
1,260,653
-146,995
-10% -$14.3M 0.02% 701
2021
Q4 		$152M Buy
1,407,648
+144,000
+11% +$15.7M 0.02% 680
2021
Q3 		$138M Buy
1,263,648
+510,006
+68% +$52.9M 0.02% 672
2021
Q2 		$70.6M Buy
753,642
+76,061
+11% +$7M 0.01% 1067
2021
Q1 		$62.4M Sell
677,581
-88,318
-12% -$7.45M 0.01% 1027
2020
Q4 		$56M Sell
765,899
-103,572
-12% -$7.7M 0.01% 1014
2020
Q3 		$67.5M Buy
869,471
+486,385
+127% +$33.5M 0.01% 766
2020
Q2 		$21.3M Buy
383,086
+33,728
+10% +$1.44M ﹤0.01% 1350
2020
Q1 		$10.3M Buy
349,358
+26,385
+8% +$893K ﹤0.01% 1739
2019
Q4 		$11.7M Buy
322,973
+34,078
+12% +$1.04M ﹤0.01% 2242
2019
Q3 		$7.87M Buy
288,895
+27,769
+11% +$718K ﹤0.01% 2374
2019
Q2 		$6.28M Sell
261,126
-198,021
-43% -$5.02M ﹤0.01% 2687
2019
Q1 		$12.1M Sell
459,147
-159,989
-26% -$3.79M ﹤0.01% 1841
2018
Q4 		$12.1M Sell
619,136
-558,341
-47% -$10.9M ﹤0.01% 1920
2018
Q3 		$23.1M Buy
1,177,477
+719,847
+157% +$13.7M 0.01% 1550
2018
Q2 		$7.58M Sell
457,630
-138,835
-23% -$2.12M ﹤0.01% 2684
2018
Q1 		$8.47M Buy
596,465
+101,094
+20% +$1.49M ﹤0.01% 2502
2017
Q4 		$7.23M Sell
495,371
-284,463
-36% -$4M ﹤0.01% 2693
2017
Q3 		$9.89M Sell
779,834
-577,866
-43% -$7.35M ﹤0.01% 2287
2017
Q2 		$16.1M Sell
1,357,700
-64,966
-5% -$808K ﹤0.01% 1714
2017
Q1 		$21M Buy
1,422,666
+531,882
+60% +$8.61M 0.01% 1514
2016
Q4 		$14.4M Sell
890,784
-517,898
-37% -$9.39M ﹤0.01% 1858
2016
Q3 		$25.5M Buy
1,408,682
+703,768
+100% +$13.7M 0.01% 1278
2016
Q2 		$11.6M Buy
704,914
+585,558
+491% +$9.47M ﹤0.01% 1856
2016
Q1 		$1.98M Sell
119,356
-428,878
-78% -$7.5M ﹤0.01% 3366
2015
Q4 		$11.9M Buy
548,234
+185,829
+51% +$3.62M ﹤0.01% 1818
2015
Q3 		$7.18M Sell
362,405
-187,096
-34% -$5.91M ﹤0.01% 2297
2015
Q2 		$19.1M Buy
549,501
+190,885
+53% +$5.83M 0.01% 1535
2015
Q1 		$9.31M Buy
358,616
+220,781
+160% +$4.05M ﹤0.01% 2121
2014
Q4 		$1.78M Sell
137,835
-203,064
-60% -$2.54M ﹤0.01% 3669
2014
Q3 		$4.19M Sell
340,899
-113,701
-25% -$1.32M ﹤0.01% 2781
2014
Q2 		$7.19M Buy
454,600
+19,085
+4% +$272K ﹤0.01% 2338
2014
Q1 		$6.58M Sell
435,515
-120,744
-22% -$1.36M ﹤0.01% 2328
2013
Q4 		$4.24M Buy
556,259
+527,667
+1,846% +$2.85M ﹤0.01% 2724
2013
Q3 		$96K Buy
+28,592
New +$75.4K ﹤0.01% 5098

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Morgan Stanley's HZNP Position: Q4 2023 in Review

Morgan Stanley sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 2,839,854 shares — an estimated $329M sold.

Morgan Stanley first reported a position in HZNP in Q3 2013 and held it in 41 quarters. The position peaked at $329M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Morgan Stanley reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 2,839,854 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $329M.
  • Morgan Stanley first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 41 quarters.
  • Morgan Stanley's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $329M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.